Main content

The Immortals: 5. The Trial

What will it take to get a drug that treats aging itself - not just the diseases of aging - to market? An entrepreneur works within the system to usher in a new era of longer life.

Loyal for Dogs is one of the companies in the longevity industry doing serious science. They are well-founded, have a killer team, and a very clear mission: to be the first to get a drug that treats ageing - not just the diseases of ageing, but ageing itself - to pass the rigorous Food and Drug Administration approval process.

Their CEO, Celine Halioua, is a maverick founder whose life has been guided by her ability to work systems. So, to meet her mission, she’s got a hack that will get her new ageing drug into trials. That will be a first for the longevity community, and the foundation stone for the next phase of our search for eternal life.

In this series, technology reporter and psychologist Aleks Krotoski explores the frontiers of the extreme longevity pioneers. They've made their money in Silicon Valley. And with their technology solutions - PayPal, Facebook, cryptocurrencies - they've ushered in the world that we live in today, with all its unintended consequences. Some of them now want to solve the "problem" of aging, or even death, and they are making bigger strides than we may think.

Can they? Should they?

A Pillowfort production for Βι¶ΉΤΌΕΔ Radio 4

New episodes released Mondays. If you're in the UK, listen to the full series of Intrigue: The Immortals first on Βι¶ΉΤΌΕΔ Sounds: bbc.in/3WEQS5W

Available now

15 minutes

Broadcast

  • Fri 8 Sep 2023 13:45

Podcast